Eagle Pharmaceuticals has gone public, raising $50 million by offering 3.35 million shares at $15 apiece, the midpoint of its $14 to $16 price range. The company, which develops and sells injectable versions of expiring patented drugs, now trades on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals previously raised nearly $58 million in VC funding, garnering a $112 million valuation in 2011. Shareholders include ProQuest Investments (43.3% pre-IPO stake), General Electric (9.0%), JAFCO (8.1%) and Prudential Financial (5.9%). The company ended its first day of trading at $12.83.